Changes in ribosome biogenesis may induce cancer by down-regulating the cell tumor suppressor potential

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1825, Issue 1, 2012, Pages 101-110

  Montanaro, Lorenzo ^a   Treré, Davide ^a   Derenzini, Massimo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Cancer; Ribosome biogenesis; Tumor suppressor

Indexed keywords

PROTEIN P53;

5Q- SYNDROME; BIOGENESIS; CANCER INHIBITION; CANCER RISK; CARCINOGENESIS; CELL GROWTH; CELL STIMULATION; DISEASE ASSOCIATION; DOWN REGULATION; GENE EXPRESSION REGULATION; HUMAN; INHERITANCE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW; RIBOSOME; RIBOSOME BIOGENESIS; TUMOR SUPPRESSOR GENE; UPREGULATION;

CELL TRANSFORMATION, NEOPLASTIC; DOWN-REGULATION; GENES, TUMOR SUPPRESSOR; HUMANS; NEOPLASMS; RIBOSOMES;

EID: 82255169340     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2011.10.006     Document Type: Review

References (135)

1. Pianese G. Beitrag zur Histologie und Aetiologie der Carcinoma. Histologische und experimentelle Untersuchungen. Beitr. Pathol. Anat. Allgem. Pathol. 1896, 142:1-193.
2. Busch H., Smetana K. Nucleoli of tumor cells. The Nucleolus 1970, 448-471. Academic Press, New York. H. Busch, K. Smetana (Eds.).
3. Maggi L.B., Weber J.D. Nucleolar adaptation in human cancer. Cancer Investig. 2005, 23:599-608.
4. Montanaro L., Treré D., Derenzini M. Nucleolus, ribosomes, and cancer. Am. J. Pathol. 2008, 173:301-310.
5. Derenzini M., Montanaro L., Treré D. What the nucleolus says to a tumour pathologist. Histopathology 2009, 54:753-762.
6. Ruggero D., Pandolfi P.P. Does the ribosome translate cancer?. Nat. Rev. Cancer 2003, 3:179-192.
7. Barna M., Pusic A., Zollo O., Costa M., Kondrashov N., Rego E., Rao P.H., Ruggero D. Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency. Nature 2008, 456:971-975.
8. Ruggero D. The role of Myc-induced protein synthesis in cancer. Cancer Res. 2009, 69:8839-8843.
9. Montanaro L., Calienni M., Bertoni S., Rocchi L., Sansone P., Storci G., Santini D., Ceccarelli C., Taffurelli M., Carnicelli D., Brigotti M., Bonafè M., Treré D., Derenzini M. Novel dyskerin mediated mechanism of p53 inactivation through defective mRNA translation. Cancer Res. 2010, 70:4767-4777.
10. Bellodi C., Kopmar N., Ruggero D. Deregulation of oncogene induced senescence and p53 translational control in X-linked dyskeratosis congenita. EMBO J. 2010, 29:1865-1876.
11. Bellodi C., Krasnykh O., Haynes N., Theodoropoulou M., Peng G., Montanaro L., Ruggero D. Loss of function of the tumor suppressor DKC1 perturbs p27 translation control and contributes to pituitary tumorigenesis. Cancer Res. 2010, 70:6026-6035.
12. Zinzalla V., Stracka D., Oppliger W., Hall M.N. Activation of mTORC2 by association with the ribosome. Cell 2011, 144:757-768.
13. Donati G., Bertoni S., Brighenti E., Vici M., Treré D., Volarevic S., Montanaro L., Derenzini M. The balance between rRNA and ribosomal protein synthesis up- and downregulates the tumour suppressor p53 in mammalian cells. Oncogene 2011, 30:3274-3288.
14. Mayer C., Grummt I. Ribosome biogenesis and cell growth: mTOR coordinates transcription by all three classes of nuclear RNA polymerases. Oncogene 2006, 25:6384-6391.
15. Kopp K., Gasiorowski J.Z., Chen D., Gilmore R., Norton J.T., Wang C., Leary D.J., Chan E.K., Dean D.A., Huang S. Pol I transcription and pre-rRNA processing are coordinated in a transcription-dependent manner in mammalian cells. Mol. Biol. Cell 2007, 18:394-403.
16. Lempiäinen H., Shore D. Growth control and ribosome biogenesis. Curr. Opin. Cell Biol. 2009, 21:855-863.
17. Grummt I. Wisely chosen paths-regulation of rRNA synthesis. FEBS J. 2010, 277:4626-4639.
18. Vladimirov S.N., Ivanov A.V., Karpova G.G., Musolyamov A.K., Egorov T.A., Thiede B., Wittmann-Liebold B., Otto A. Characterization of the human small-ribosomal-subunit proteins by N-terminal and internal sequencing, and mass spectrometry. Eur. J. Biochem. 1996, 239:144-1499.
19. Odintsova T.I., Müller E.C., Ivanov A.V., Egorov T.A., Bienert R., Vladimirov S.N., Kostka S., Otto A., Wittmann-Liebold B., Karpova G.G. Characterization and analysis of posttranslational modifications of the human large cytoplasmic ribosomal subunit proteins by mass spectrometry and Edman sequencing. J. Protein Chem. 2003, 22:249-258.
20. Fatica A., Tollervey D. Making ribosomes. Curr. Opin. Cell Biol. 2002, 14:313-318.
21. Fromont-Racine M., Senger B., Saveanu C., Fasiolo F. Ribosome assembly in eukaryotes. Gene 2003, 313:17-42.
22. Tschochner H., Hurt E. Pre-ribosomes on the road from the nucleolus to the cytoplasm. Trends Cell Biol. 2003, 13:255-263.
23. Kressler D., Hurt E., Bassler J. Driving ribosome assembly. Biochim. Biophys. Acta 2010, 1803:673-683.
24. Chedin S., Laferte A., Hoang T., Lafontaine D.L., Riva M., Carles C. Is ribosome synthesis controlled by pol I transcription?. Cell Cycle 2007, 6:11-15.
25. Lam Y.W., Lamond A.I., Mann M., Andersen J.S. Analysis of nucleolar protein dynamics reveals the nuclear degradation of ribosomal proteins. Curr. Biol. 2007, 17:749-760.
26. Grummt I. Life on a planet of its own: regulation of RNA polymerase I transcription in the nucleolus. Genes Dev. 2003, 17:1691-1702.
27. Goodfellow S.J., White R.J. Regulation of RNA polymerase III transcription during mammalian cell growth. Cell Cycle 2007, 6:2323-2326.
28. White R.J. RNA polymerase III transcription and cancer. Oncogene 2004, 23:3208-3216.
29. White R.J. RNA polymerases I and III, growth control and cancer. Nat. Rev. Mol. Cell Biol. 2005, 6:69-78.
30. Thomas G. An encore for ribosome biogenesis in the control of cell proliferation. Nat. Cell Biol. 2000, 2:E71-E72.
31. Conlon I., Raff M. Size control in animal development. Cell 1999, 96:235-244.
32. Schmidt E.V. The role of c-myc in cellular growth control. Oncogene 1999, 18:2988-2996.
33. Stefanovsky V., Langlois F., Gagnon-Kugler T., Rothblum L.I., Moss T. Growth factor signaling regulates elongation of RNA polymerase I transcription in mammals via UBF phosphorylation and r-chromatin remodeling. Mol. Cell 2006, 21:629-639.
34. Stefanovsky V.Y., Pelletier G., Hannan R., Gagnon-Kugler T., Rothblum R.I., Moss T. An immediate response of ribosomal transcription to growth factor stimulation in mammals is mediated by ERK phosphorylation of UBF. Mol. Cell 2001, 8:1063-1073.
35. Zhu J., Blenis J., Yuan J. Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:6584-6589.
36. Gomez-Roman N., Felton-Edkins Z.A., Kenneth N.S., Goodfellow S.J., Athineos D., Zhang J., Ramsbottom B.A., Innes F., Kantidakis T., Kerr E.R., Brodie J., Grandori C., White R.J. Activation by c-Myc of transcription by RNA polymerases I, II and III. Biochem. Soc. Symp. 2006, 73:141-154.
37. van Riggelen J., Yetil A., Felsher D.W. MYC as a regulator of ribosome biogenesis and protein synthesis. Nat. Rev. Cancer 2010, 4:301-309.
38. Cavanaugh A.H., Hempel W.M., Taylor L.J., Rogalsky V., Todorov G., Rothblum L.I. Activity of RNA polymerase I transcription factor UBF blocked by Rb gene product. Nature 1995, 374:177-180.
39. Voit R., Schafer K., Grummt I. Mechanism of repression of RNA polymerase I transcription by the retinoblastoma protein. Mol. Cell. Biol. 1997, 17:4230-4237.
40. Hannan K.M., Hannan R.D., Smith S.D., Jefferson L.S., Lun M., Rothblum L.I. Rb and p130 regulate RNA polymerase I transcription: Rb disrupts the interaction between UBF and SL-1. Oncogene 2000, 19:4988-4999.
41. Ciarmatori S., Scott P.H., Sutcliffe J.E., McLees A., Alzuherri H.M., Dannenberg J.H., Te Riele H., Grummt I., Voit R., White R.J. Overlapping functions of the ppRB family in the regulation of rRNA synthesis. Mol. Cell. Biol. 2001, 21:5806-5814.
42. White R.J., Trouche D., Martin K., Jackson S.P., Kouzarides T. Repression of RNA polymerase III transcription by the retinoblastoma protein. Nature 1996, 382:88-90.
43. Felton-Edkins Z.A., Kenneth N.S., Brown T.R., Daly N.L., Gomez-Roman N., Grandori C., Eisenman R.N., White R.J. Direct regulation of RNA polymerase III transcription by RB, p53 and c-Myc. Cell Cycle 2003, 2:181-184.
44. Zhai W., Comai L. Repression of RNA polymerase I transcription by the tumor suppressor p53. Mol. Cell. Biol. 2000, 20:5930-5938.
45. Ayrault O., Andrique L., Fauvin D., Eymin B., Gazzeri S., Seite P. Human tumor suppressor p14ARF negatively regulates rRNA transcription and inhibits UBF1 transcription factor phosphorylation. Oncogene 2006, 25:7577-7586.
46. Itahana K., Bhat K.P., Jin A., Itahana Y., Hawke D., Kobayashi R., Zhang Y. Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation. Mol. Cell 2003, 12:1151-1164.
47. Zhang C., Comai L., Johnson D.L. Expression of PTEN in PTEN-deficient cells represses Pol I transcription by disrupting the SL1 complex. Mol. Cell. Biol. 2005, 25:6899-6911.
48. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
49. Knudsen E.S., Knudsen K.E. Tailoring to RB: tumour suppressor status and therapeutic response. Nat. Rev. Cancer 2008, 8:714-724.
50. Vogelstein B., Lane D., Levine A.J. Surfing the p53 network. Nature 2000, 408:307-310.
51. Vousden K.H., Lane D.P. p53 in health and disease. Nat. Rev. Mol. Cell Biol. 2007, 8:275-283.
52. Sherr C.J. The INK4a/ARF network in tumour suppression. Nat. Rev. Mol. Cell Biol. 2001, 2:731-737.
53. Lowe S.W., Sherr C.J. Tumor suppression by Ink4a-Arf: progress and puzzles. Curr. Opin. Genet. Dev. 2003, 13:77-83.
54. Yin Y., Shen W.H. PTEN: a new guardian of the genome. Oncogene 2008, 27:5443-5453.
55. Derenzini M., Montanaro L., Chillà A., Tosti E., Vici M., Barbieri S., Govoni M., Mazzini G., Treré D. Key role of the achievement of an appropriate ribosomal RNA complement for G1-S phase transition in H4-II-E-C3 rat hepatoma cells. J. Cell. Physiol. 2005, 202:483-491.
56. Helpap B. Observations on the number, size and localization of nucleoli in hyperplastic and neoplastic prostatic disease. Histopathology 1988, 13:203-211.
57. Wilkinson N., Buckley C.H., Chawner L., Fox H. Nucleolar organiser regions in normal, hyperplastic, and neoplastic endometria. Int. J. Gynecol. Pathol. 1990, 9:55-59.
58. Helpap B., Riede C. Nucleolar and AgNOR-analysis of prostatic intraepithelial neoplasia (PIN), atypical adenomatous hyperplasia (AAH) and prostatic carcinoma. Pathol. Res. Pract. 1995, 191:381-390.
59. Tuccari G., Abbona G.C., Giuffrè G., Papotti M., Gasparri G., Barresi G., Bussolati G. AgNOR quantity as a prognostic tool in hyperplastic and neoplastic parathyroid glands. Virchows Arch. 2000, 437:298-303.
60. Lloyd S.N., Johnson C.P., Brown I.L., Kirk D. Nucleolar organizer regions in benign and malignant prostatic disease. Histopathology 1991, 18:449-452.
61. Papadimitiou C.S., Athanasiadou S., Stylianidou A., Karameris A. Nucleolar organizer regions in the normal, hyperplastic and carcinomatous epithelium of endometrium. Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 1991, 60:155-160.
62. Crocker J. Nucleolar organiser regions. Curr. Top. Pathol. 1990, 82:91-149.
63. Derenzini M., Ploton D. Interphase nucleolar organizer regions in cancer cells. Int. Rev. Exp. Pathol. 1991, 32:149-192.
64. Derenzini M., Ploton D. Interphase nucleolar organizer regions. Molecular Biology in Histopathology 1994, 121-149. John Wiley & Sons Ltd. J. Crocker (Ed.).
65. Derenzini M., Trerè D., Pession A., Montanaro L., Sirri V., Ochs R.L. Nucleolar function and size in cancer cells. Am. J. Pathol. 1998, 152:1291-1297.
66. Derenzini M., Trerè D., Pession A., Govoni M., Sirri V., Chieco P. Nucleolar size indicates the rapidity of cell proliferation in cancer tissues. J. Pathol. 2000, 191:181-186.
67. Werness B.A., Levine A.J., Howley P.M. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990, 248:76-79.
68. Dyson N., Howley P.M., Munger K., Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989, 243:934-937.
69. Wang H.D., Trivedi A., Johnson D.L. Regulation of RNA polymerase I-dependent promoters by the hepatitis B virus X protein via activated Ras and TATA-binding protein. Mol. Cell. Biol. 1998, 18:7086-7094.
70. Aufiero B., Schneider R.J. The hepatitis B virus X-gene product transactivates both RNA polymerase II and III promoters. EMBO J. 1990, 9:497-504.
71. Fukutomi T., Zhou Y., Kawai S., Eguchi H., Wands J.R., Li J. Hepatitis C virus core protein stimulates hepatocyte growth: correlation with upregulation of wnt-1 expression. Hepatology 2005, 41:1096-1105.
72. Kawamura H., Govindarajan S., Aswad F., Machida K., Lai M.M., Sung V.M., Dennert G. HCV core expression in hepatocytes protects against autoimmune liver injury and promotes liver regeneration in mice. Hepatology 2006, 44:936-944.
73. Kao C.F., Chen S.Y., Lee Y.H. Activation of RNA polymerase I transcription by hepatitis C virus core protein. J. Biomed. Sci. 2004, 11:72-94.
74. Derenzini M., Trerè D., Oliveri F., David E., Colombatto P., Bonino F., Brunetto M.R. Is high AgNOR quantity in hepatocytes associated with increased risk of hepatocellular carcinoma in chronic liver disease?. J. Clin. Pathol. 1993, 46:727-729.
75. Trere' D., Borzio M., Morabito A., Borzio F., Roncalli M., Derenzini M. Nucleolar hypertrophy correlates with hepatocellular carcinoma development in cirrhosis due to HBV infection. Hepatology 2003, 37:72-78.
76. Frescas D., Guardavaccaro D., Bassermann F., Koyama-Nasu R., Pagano M. JHDM1B/FBXL10 is a nucleolar protein that represses transcription of ribosomal RNA genes. Nature 2007, 450:309-313.
77. Guetg C., Lienemann P., Sirri V., Grummt I., Hernandez-Verdun D., Hottiger M.O., Fussenegger M., Santoro R. The NoRC complex mediates the heterochromatin formation and stability of silent rRNA genes and centromeric repeats. EMBO J. 2010, 29:2135-2146.
78. Belin S., Beghin A., Solano-Gonzàlez E., Bezin L., Brunet-Manquat S., Textoris J., Prats A.C., Mertani H.C., Dumontet C., Diaz J.J. Dysregulation of ribosome biogenesis and translational capacity is associated with tumor progression of human breast cancer cells. PLoS One 2009, 4:e7147.
79. Rossetti S., Hoogeveen A.T., Esposito J., Sacchi N. Loss of MTG16a (CBFA2T3), a novel rDNA repressor, leads to increased ribogenesis and disruption of breast acinar morphogenesis. J. Cell Mol. Med. 2010, 14:1358-1370.
80. Oliver E.R., Saunders T.L., Tarlé S.A., Glaser T. Ribosomal protein L24 defect in belly spot and tail (Bst), a mouse Minute. Development 2004, 131:3907-3920.
81. Mayer C., Grummt I. Cellular stress and nucleolar function. Cell Cycle 2005, 4:1036-1038.
82. Opferman J.T., Zambetti G.P. Translational research? Ribosome integrity and a new p53 tumor suppressor checkpoint. Cell Death Differ. 2006, 13:898-901.
83. Panic L., Montagne J., Cokaric M., Volarevic S. S6-haploinsufficiency activates the p53 tumor suppressor. Cell Cycle 2007, 6:20-24.
84. Deisenroth C., Zhang Y. Ribosome biogenesis surveillance: probing the ribosomal protein-Mdm2-p53 pathway. Oncogene 2010, 29:4253-4260.
85. Sherr C.J., Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999, 13:1501-1512.
86. Zhang Y., Lu H. Signaling to p53: ribosomal proteins find their way. Cancer Cell 2009, 16:369-377.
87. Momand J., Zambetti G.P., Olson D.C., George D., Levine A.J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992, 69:1237-1245.
88. Haupt Y., Maya R., Kazaz A., Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997, 387:296-299.
89. Kubbutat M.H., Jones S.N., Vousden K.H. Regulation of p53 stability by Mdm2. Nature 1997, 387:299-303.
90. Zhang Y., Wolf G.W., Bhat K., Jin A., Allio T., Burkhart W.A., Xiong Y. Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates p53-dependent ribosomal-stress checkpoint pathway. Mol. Cell. Biol. 2003, 23:8902-8912.
91. Sun X.X., Dai M.S., Lu H. 5-fluorouracil activation of p53 involves an MDM2-ribosomal protein interaction. J. Biol. Chem. 2007, 282:8052-8059.
92. Sun X.X., Dai M.S., Lu H. Mycophenolic acid activation of p53 requires ribosomal proteins L5 and L11. J. Biol. Chem. 2008, 282:12387-12392.
93. Yuan X., Zhou Y., Casanova E., Chai M., Kiss E., Gröne H.J., Schütz G., Grummt I. Genetic inactivation of the transcription factor TIF-IA leads to nucleolar disruption, cell cycle arrest, and p53-mediated apoptosis. Mol. Cell 2005, 19:77-87.
94. Lohrum M.A.E., Ludwig R.L., Kubbutat M.H.G., Hanlon M., Vousden K.H. Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell 2003, 3:577-587.
95. Bhat K.P., Itahana K., Jin A., Zhang Y. Essential role of ribosomal protein L11 in mediating growth inhibition induced p53 activation. EMBO J. 2004, 23:2402-2412.
96. Dai M.S., Lu H. Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. J. Biol. Chem. 2004, 279:44475-44482.
97. Dai M.S., Zeng S.X., Jin Y., Sun X.X., David L., Lu H. Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition. Mol. Cell. Biol. 2004, 24:7654-7668.
98. Jin A., Itahana K., O'Keefe K., Zhang Y. Inhibition of HDM2 and activation of p53 by ribosomal protein L23. Mol. Cell. Biol. 2004, 24:7669-7680.
99. Rubbi C.P., Milner J. Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses. EMBO J. 2003, 22:6068-6077.
100. Macias E., Jin A., Deisenroth C., Bhat K., Mao H., Lindström M.S., Zhang Y. An ARF-independent c-MYC-activated tumor suppression pathway mediated by ribosomal protein-Mdm2 interaction. Cancer Cell 2010, 18:231-243.
101. Narla A., Ebert B.L. Ribosomopathies: human disorders of ribosome dysfunction. Blood 2010, 115:3196-3205.
102. Dokal I. Dyskeratosis congenita in all its forms. Br. J. Haematol. 2000, 110:768-779.
103. Alter B.P., Giri N., Savage S.A., Peters J.A., Loud J.T., Leathwood L., Carr A.G., Greene M.H., Rosenberg P.S. Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. Br. J. Haematol. 2010, 150:179-188.
104. Kiss T. Small nucleolar RNA-guided post-transcriptional modification of cellular RNAs. EMBO J. 2001, 20:3617-3622.
105. Meier U.T. How a single protein complex accommodates many different H/ACA RNAs. Trends Biochem. Sci. 2006, 31:311-315.
106. Mitchell J.R., Wood E., Collins K. A telomerase component is defective in the human disease dyskeratosis congenita. Nature 1999, 402:551-555.
107. Ruggero D., Grisendi S., Piazza F., Rego E., Mari F., Rao P.H., Cordon-Cardo C., Pandolfi P.P. Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification. Science 2003, 2003(299):259-262.
108. Baudin-Baillieu A., Fabret C., Liang X.H., Piekna-Przybylska D., Fournier M.J., Rousset J.P. Nucleotide modifications in three functionally important regions of the Saccharomyces cerevisiae ribosome affect translation accuracy. Nucleic Acids Res. 2009, 37:7665-7677.
109. Yoon A., Peng G., Brandenburger Y., Zollo O., Xu W., Rego E., Ruggero D. Impaired control of IRES-mediated translation in X-linked dyskeratosis congenita. Science 2006, 312:902-906.
110. Hellen C.U., Sarnow P. Internal ribosome entry sites in eukaryotic mRNA molecules. Genes Dev. 2001, 15:1593-1612.
111. Hermanns P., Bertuch A.A., Bertin T.K., Dawson B., Schmitt M.E., Shaw C., Zabel B., Lee B. Consequences of mutations in the non coding RMRP RNA in cartilage-hair hypoplasia. Hum. Mol. Genet. 2005, 14:3723-3740.
112. Ganapathi K.A., Austin K.M., Lee C.S., Dias A., Malsch M.M., Reed R., Shimamura A. The human Shwachman-Diamond syndrome protein, SBDS, associates with ribosomal RNA. Blood 2007, 110:1458-1465.
113. Hesling C., Oliveira C.C., Castilho B.A., Zanchin N.I. The Shwachman-Bodian-Diamond syndrome associated protein interacts with HsNip7 and its down-regulation affects gene expression at the transcriptional and translational levels. Exp. Cell Res. 2007, 313:4180-4195.
114. Draptchinskaia N., Gustavsson P., Andersson B., Pettersson M., Willig T.N., Dianzani I., Ball S., Tchernia G., Klar J., Matsson H., Tentler D., Mohandas N., Carlsson B., Dahl N. The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia. Nat. Genet. 1999, 21:169-175.
115. Da Costa L., Tchernia G., Gascard P., Lo A., Meerpohl J., Niemeyer C., Chasis J.A., Fixler J., Mohandas N. Nucleolar localization of RPS19 protein in normal cells and mislocalization due to mutations in the nucleolar localization signals in 2 Diamond-Blackfan anemia patients: potential insights into pathophysiology. Blood 2003, 101:5039-5045.
116. Gazda H.T., Grabowska A., Merida-Long L.B., Latawiec E., Schneider H.E., Lipton J.M., Vlachos A., Atsidaftos E., Ball S.E., Orfali K.A., Niewiadomska E., Da Costa L., Tchernia G., Niemeyer C., Meerpohl J.J., Stahl J., Scratt G., Glader B., Backer K., Wong C., Nathan D.G., Beggs A.H., Sieff C.A. Ribosomal protein S24 gene is mutated in Diamond-Blackfan anemia. Am. J. Hum. Genet. 2006, 79:1110-1118.
117. Cmejla R., Cmejlova J., Handrkova H., Petrak J., Pospisilova D. Ribosomal protein S17 gene (RPS17) is mutated in Diamond-Blackfan anemia. Hum. Mutat. 2007, 28:1178-1182.
118. Farrar J.E., Nater M., Caywood E., McDevitt M.A., Kowalski J., Takemoto C.M., Talbot C.C., Meltzer P., Esposito D., Beggs A.H., Schneider H.E., Grabowska A., Ball S.E., Niewiadomska E., Sieff C.A., Vlachos A., Atsidaftos E., Ellis S.R., Lipton J.M., Gazda H.T., Arceci R.J. Abnormalities of the large ribosomal subunit protein, Rpl35a, in Diamond-Blackfan anemia. Blood 2008, 112:1582-1592.
119. Gazda H.T., Sheen M.R., Vlachos A., Choesmel V., O'Donohue M.F., Schneider H., Darras N., Hasman C., Sieff C.A., Newburger P.E., Ball S.E., Niewiadomska E., Matysiak M., Zaucha J.M., Glader B., Niemeyer C., Meerpohl J.J., Atsidaftos E., Lipton J.M., Gleizes P.E., Beggs A.H. Ribosomal protein L5 and L11 mutations are associated with cleft palate and abnormal thumbs in Diamond-Blackfan anemia patients. Am. J. Hum. Genet. 2008, 83:769-780.
120. Danilova N., Sakamoto K.M., Lin S. Ribosomal protein S19 deficiency in zebrafish leads to developmental abnormalities and defective erythropoiesis through activation of p53 protein family. Blood 2008, 112:5228-5237.
121. McGowan K.A., Mason P.J. Animal models of diamond blackfan anemia. Semin. Hematol. 2011, 48:106-116.
122. Fumagalli S., Thomas G. The role of p53 in ribosomopathies. Semin. Hematol. 2011, 48:97-105.
123. Montanaro L., Brigotti M., Clohessy J., Barbieri S., Ceccarelli C., Santini D., Taffurelli M., Calienni M., Teruya-Feldstein J., Trerè D., Pandolfi P.P., Derenzini M. Dyskerin expression influences the level of ribosomal RNA pseudo-uridylation and telomerase RNA component in human breast cancer. J. Pathol. 2006, 210:10-18.
124. Tanaka R., Satoh H., Moriyama M., Satoh K., Morishita Y., Yoshida S., Watanabe T., Nakamura Y., Mori S. Intronic U50 small-nucleolar-RNA (snoRNA) host gene of no protein-coding potential is mapped at the chromosome breakpoint t(3;6)(q27;q15) of human B-cell lymphoma. Genes Cells 2000, 5:277-287.
125. Dong X.Y., Rodriguez C., Guo P., Sun X., Talbot J.T., Zhou W., Petros J., Li Q., Vessella R.L., Kibel A.S., Stevens V.L., Calle E.E., Dong J.T. SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer. Hum. Mol. Genet. 2008, 17:1031-1042.
126. Mourtada-Maarabouni M., Pickard M.R., Hedge V.L., Farzaneh F., Williams G.T. GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer. Oncogene 2009, 28:195-208.
127. Dong X.Y., Guo P., Boyd J., Sun X., Li Q., Zhou W., Dong J.T. Implication of snoRNA U50 in human breast cancer. J. Genet. Genomics 2009, 36:447-454.
128. Kiss-László Z., Henry Y., Bachellerie J.P., Caizergues-Ferrer M., Kiss T. Site-specific ribose methylation of preribosomal RNA: a novel function for small nucleolar RNAs. Cell 1996, 85:1077-1088.
129. Ebert B.L., Pretz J., Bosco J., Chang C.Y., Tamayo P., Galili N., Raza A., Root D.E., Attar E., Ellis S.R., Golub T.R. TR. Identification of RPS14 as a 5q-syndrome gene by RNA interference screen. Nature 2008, 451:335-339.
130. Ebert B.L. Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer. Leukemia 2009, 23:1252-1256.
131. Renehan A.G., Frystyk J., Flyvbjerg A. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol. Metab. 2006, 17:328-336.
132. Renehan A.G., Roberts D.L., Dive C. Obesity and cancer: pathophysiological and biological mechanisms. Arch. Physiol. Biochem. 2008, 114:71-83.
133. Frasca F., Pandini G., Sciacca L., Pezzino V., Squatrito S., Belfiore A., Vigneri R. The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch. Physiol. Biochem. 2008, 114:23-37.
134. Cannata D., Fierz Y., Vijayakumar A., LeRoith D. Type 2 diabetes and cancer: what is the connection?. Mt. Sinai J. Med. 2010, 77:197-213.
135. Nalepa G., Rolfe M., Harper J.W. Drug discovery in the ubiquitin-proteasome system. Nat. Rev. Drug Discov. 2006, 5:596-613.